| Name | Title | Contact Details |
|---|
Silverstein Properties, Inc. (SPI) is a privately-held, full-service real estate development, investment and management firm based in New York. Founded in 1957 by President and CEO Larry Silverstein, SPI has developed, owned, and managed more than 35 million square feet of office, residential, hotel, and retail properties in the United States. For the past few years, SPI has been named one of the "Best Places to Work in New York City" by Crain`s New York Business. Currently, the firm has $10 billion of development underway: Four Seasons Resort at Walt Disney World, Four Seasons Downtown New York Hotel and Private Luxury Residences and World Trade Center Towers 2, 3 and 4 in New York. In addition, SPI is focused on joint ventures for development and acquisitions in Europe, Asia and the Middle East. The company is known for developing first-class projects, repositioning older buildings, and providing first-rate services that enhance value for investors and quality of life for tenants. SPI`s properties are thriving, highly regarded places that sustain their appeal and profitability over time. As a result, current occupancy levels are well above industry benchmarks for the firm`s commercial and residential portfolio, which includes 9 million square feet of office, residential and retail properties in Midtown and Downtown Manhattan.
Gents- LLC is a New York, NY-based company in the Business Services sector.
Apellis Pharmaceuticals is a global biopharmaceutical company based in Waltham, Massachusetts. The company is focused on developing innovative therapies that target the complement system, a crucial part of the immune system. Apellis aims to create life-changing treatments for various debilitating diseases through its commitment to scientific research and patient care. The company has a diverse pipeline of products, including EMPAVELI, which is approved for treating paroxysmal nocturnal hemoglobinuria and is being investigated for other conditions. SYFOVRE is in development for geographic atrophy, along with a combination therapy involving APL-APL-3007. Apellis is also exploring RNA therapies and gene-edited treatments for multiple therapeutic areas. With a global presence in countries such as the US, Canada, and several European nations, Apellis serves patients and healthcare providers affected by diseases related to the complement system. The company reported approximately $709 million in U.S. net product revenues for the full year 2024, reflecting its strong market position and commitment to advancing its therapeutic offerings.
Land Data Technologies Inc. is a Edmonton, AB-based company in the Business Services sector.
iboost.com is a North Hollywood, CA-based company in the Business Services sector.